ArticleActa dermato-venereologica2020
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Article in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.Clinical and experimental rheumatology · 2023Pooled it
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases.Frontiers in medicine · 2026Article
- Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review.Frontiers in immunology · 2025Review
- Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.Expert opinion on pharmacotherapy · 2024Review
- Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review.Life (Basel, Switzerland) · 2023Review
- Past, Present, and Future in Dermatomyositis Therapeutics.Current treatment options in rheumatology · 2022Article
- Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib.Modern rheumatology case reports · 2022Article
- The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.Clinical rheumatology · 2021Review
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.Clinical, cosmetic and investigational dermatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
is missing (Short communication).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.